RIPK4 and viral infectious disease: To further validate our hits and provide ready-to-trial drugs capable of stopping viral infection/replication of current and future variants, we screened a number of FDA-approved drugs for unrelated diseases and chemical compounds reported to interfere with the most common viral host factor candidates (SLC7A11, RIPK4, and MASTL).